Grant ID RP160121
Awarded On November 19, 2015
Title Clinical Safety and Efficacy of Third party, fucosylated, cord blood derived regulatory T cells to prevent graft versus host disease
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Borje Andersson
Cancer Sites Leukemia, Lymphoma, Myeloma
Contracted Amount $891,714
Lay Summary

Graft versus host disease (GVHD) is a life threatening complication of allogeneic stem cell transplantation with limited therapeutic options. GVHD is primarily mediated by the donor derived T-cells and the currently available treatments are directed towards suppressing T-cells. Such therapies lead to generalized immunesuppression and are associated with toxic side effects including increased rates of infection and kidney failure. Promising, novel, cell-based therapies including naturally occurring regulatory T cells (Tregs) are being explored by the transplant community to improve outcomes. However, a major limitation in its clinical application is the low cell dose of Tregs, since it only c...

Read More